HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Harmony Biosciences Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$37.54−0.41 (-1.08%)
Close on Oct 19, 2026
- Market cap
- $2.21B
- P/E (TTM)
- 12.1
- Dividend yield
- –
Harmony Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Market Cap | $2.19B | $166.30M |
| Enterprise Value | $1.67B | $87.12M |
| PE Ratio | 12.15 | 19.67 |
| PS Ratio | 2.28 | 3.60 |
| PB Ratio | 2.19 | 2.03 |
| P/TBV Ratio | 2.37 | 2.31 |
| P/OCF Ratio | 6.16 | 13.32 |
Enterprise value
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| EV / Sales | 1.74 | 2.43 |
| EV / EBITDA | 7.25 | 14.69 |
| EV / EBIT | 7.25 | 18.47 |
Income (trailing twelve months)
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Revenue | $959.90M | $57.94M |
| Gross Profit | $723.99M | $90.47M |
| Operating Income | $230.65M | -$21.49M |
| Pretax Income | $241.20M | -$14.72M |
| Net Income | $181.27M | -$22.46M |
| EBITDA | $230.65M | -$17.14M |
| EPS (Diluted) | $3.09 | -$0.83 |
Margins
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Gross Margin | 75.4% | 52.3% |
| Operating Margin | 24.0% | -44.5% |
| Pretax Margin | 25.1% | -13.0% |
| Profit Margin | 18.9% | -39.2% |
| EBITDA Margin | 24.0% | -31.3% |
Returns
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Return on Equity (ROE) | 20.5% | -53.2% |
| Return on Assets (ROA) | 14.6% | -41.0% |
| Return on Invested Capital (ROIC) | 40.1% | -32.2% |
| Return on Capital Employed (ROCE) | 20.3% | -38.0% |
Growth
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 24.3% | 6.01% |
| Net Income Growth (YoY) | 0.20% | -37.7% |
| EPS Growth (YoY) | -0.32% | -29.2% |
| Revenue Growth (3Y CAGR) | 25.6% | 2.25% |
| Revenue Growth (5Y CAGR) | 40.3% | 6.42% |
| EPS Growth (3Y CAGR) | -3.01% | -0.17% |
Balance sheet
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $667.79M | $62.64M |
| Total Debt | $153.96M | $120.13M |
| Net Cash (Debt) | $513.83M | $15.77M |
| Net Cash Per Share | $8.82 | $0.66 |
| Equity (Book Value) | $999.24M | $48.61M |
| Book Value Per Share | $17.16 | $1.36 |
| Tangible Book Value | $921.75M | $23.01M |
| Working Capital | $580.26M | $75.09M |
Financial position
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Current Ratio | 3.48 | 3.30 |
| Quick Ratio | 3.33 | 2.39 |
| Debt / Equity | 0.15 | 0.51 |
| Debt / EBITDA | 0.67 | 3.35 |
| Net Debt / EBITDA | -2.23 | 2.22 |
| Interest Coverage | 17.12 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | $355.08M | -$12.39M |
Efficiency
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.77 | 0.38 |
| Inventory Turnover | 37.87 | 2.67 |
| Revenue Per Employee | $3.28M | $398.96K |
| Profits Per Employee | $618.67K | -$705.27K |
| Employee Count | 293 | 74 |
Dividends and yields
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Earnings Yield | 8.29% | -22.8% |
Shares
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 58,236,400 | 58,139,000 |
| Shares Change (YoY) | 0.40% | 11.1% |
| Shares Change (QoQ) | 0.44% | 0.54% |
| Float | 51,215,100 | 49,154,900 |
| Shares Held by Insiders | 12.1% | 11.6% |
| Shares Held by Institutions | 93.0% | 59.4% |
Taxes
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Income Tax | $59.93M | $89.00K |
| Effective Tax Rate | 24.8% | 20.5% |
Scores
| Measure | Harmony Biosciences | Industry median |
|---|---|---|
| Graham Number | $34.54 | $17.04 |
| Graham Upside | -7.99% | -44.3% |
| Altman Z-Score | 5.54 | -0.27 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Harmony Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.